BRAF mutations have previously been detected in ALK-positive NSCLC patients after crizotinib and ceritinib treatment, and researchers argued that BRAF V600E may be a downstream pathway of ALK and cause resistance to ALK inhibitors.[14,15] To our knowledge, this is the first successfully cured patient who harbored coexistence of ALK and BRAF V600E prior to treatment; A similar case of squamous cell carcinoma who died before receiving crizotinib was reported by D. ALrifai.[16] Whether the co-mutation affects the choice of tyrosine kinase inhibitors drugs is still not clearly established. This evidence concerns the gene ALK and squamous cell carcinoma.